

Wakix Enrollment Form

Fax Referral To: 855-297-1270 Phone: 1-888-280-1190 or 787-759-4162

Email Referral To: <u>Customer.ServiceFax@CVSHealth.com</u>
Address: 280 Avenida Jesus T. Pinero Ste B Rio Piedras, PR 00927

	Six Simple St	teps to Submitting a Refer	ral		
PATIENT INFORMATION (Compl	ete or include de	mographic sheet)			
Patient Name:		DOB:		_Gender: 🗌 Male	☐ Female
Address:					
City, State, ZIP Code:					
Preferred Contact Methods: Phone (to property of the property	act via text or email,	, Specialty Pharmacy will attempt t	to contact by pho	one.	
Best time to reach me: Morning After f Minor , Parent/Caregiver/Guardian Na	rnoon 🗌 Evening	g Last Four of SSN:	Primary	/ Language:	
			Relation	ship to minor:	
PRESCRIBER INFORMATION					
Prescriber's Name:		State Li	icense #:		
NPI #: Group or Hosp	 oital:				
Address:					
City, State, ZIP Code:			Phone	ə:	
Fax: Conta	Contact Person:		Phone: Contact's Phone:		
Is the Patient Insured?	Medical Inst	Policy H urance:	Iolder's DOB: _	 _Telephone:	
Policy ID: Group #: _		Prescription Insurance	ce:		
Prescription Plan Telephone: Group #: F		Poli	CY ID:		
Group #: F ☐ Check box if patient is enrolled in mai	(X BIN #:		RX PCIN #	#: •	
_ Check box ii patient is enrolled in mai	iuracturer copa	ay assistance in yes, pleas	e provide ib#	•	
4 DIAGNOSIS AND CLINICAL IN	FORMATION	1			
Patient Clinical Information:					
Needs by date:					
Has patient previously been treated for I	Narcolepsy? \square	Yes No If YES, list all p	orevious medi	cations:	
List concomitant medications (e.g., stim	ulants, sodium	oxybate):			
		ignosis (ICD-10):			
G47.41 Narcolepsy		G47.42 Narcolepsy in cond			
G47.411 Narcolepsy with cataplexy		G47.421 Narcolepsy in con	nditions classi	fied elsewhere w/	cataplexy

Other Code:

G47.419 Narcolepsy without cataplexy

Description

Wakix Enrollment Form

Patient Name:	Patient DOB:					
Prescriber Name:	Prescriber Phone:					
5 PRESCRIPTION	INFORMATION					
	enance dose of 17.8mg	J				
MEDICATION	STRENGTH, QUANTITY/REFILLS		DOSE & DIRECTIONS			
Wakix (pitolisant) oral tablets	4.45 mg tablet #14 17.8 mg tablet #23 Refills: None	$\ \ \ \ \ \ \ \ \ \ \ \ \ $				
Wakix (pitolisant)	17.8mg tablet #30	Maintenance Dose: Take 17.8 mg (one 17.8 mg tablet) by mouth once daily in the				
oral tablets	Refills:	morning, as soon as you wake up				
Titration to and Maint	enance dose of 35.6mg	g				
MEDICATION	MEDICATION STRENGTH, DOSE & DIRECTIONS QUANTITY/REFILLS					
Wakix (pitolisant) oral tablets Wakix (pitolisant) oral tablets Non-Standard Dosing	4.45mg tablet #14 17.8mg tablet #39 Refills: None 17.8mg tablet #60 Refills:	☐ <u>Titration Dose:</u> Take 8.9 mg (two x 4.45mg tabs) by mouth once daily in the morning, upon awakening x 7 days; then take 17.8 mg (one x 17.8mg tabs) by mouth once daily in the morning, upon awakening x 7 days; then increase to take 35.6 mg (two x 17.8mg tabs) by mouth once daily in the morning, upon awakening x 16 days ☐ <u>Maintenance Dose:</u> Take 35.6 mg (two 17.8mg tablets) by mouth once daily in the morning, as soon as you wake up				
MEDICATION	STRENGTH		DOSE & DIRECTIONS	QUANTITY/REFILLS		
☐ Wakix (pitolisant) oral tablets		Other:		Quantity:		
Wakix (pitolisant) oral tablets		Other:		Quantity:		
6 PRE	SCRIBER SIGNATU	JRE REQUIRED	(STAMP SIGNATURE NOT			
"Dispense As Written"/Brand Medically Necessary/ Do Not Substitute/No Substitution/DAW/May Not Substitute		stitute	May Substitute/Product Selection Permitted/Substitution Permissible			
Prescriber's Signature:Date		Date:	Prescriber's Signature:	Date:		
	nange is mandated unless Pre		ds "No Substitution"			

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty® Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty® and/or one of its affiliates.